Back to Search
Start Over
Chemotherapy in Cutaneous Melanoma: Is There Still a Role?
- Source :
-
Current oncology reports [Curr Oncol Rep] 2023 Jun; Vol. 25 (6), pp. 609-621. Date of Electronic Publication: 2023 Mar 29. - Publication Year :
- 2023
-
Abstract
- Purpose of Review: In the preceding decade, the management of metastatic cutaneous melanoma has been revolutionised with the development of highly effective therapies including immune checkpoint inhibitors (specifically CTLA-4 and PD-1 inhibitors) and targeted therapies (BRAF and MEK inhibitors). The role of chemotherapy in the contemporary management of melanoma is undefined.<br />Recent Findings: Extended analyses highlight substantially improved 5-year survival rates of approximately 50% in patients with metastatic melanoma treated with first-line therapies. However, most patients will progress on these first-line treatments. Sequencing of chemotherapy following failure of targeted and immunotherapies is associated with low objective response rates and short progression-free survival, and thus, meaningful benefits to patients are minimal. Chemotherapy has limited utility in the contemporary management of cutaneous melanoma (with a few exceptions, discussed herein) and should not be the standard treatment sequence following failure of first-line therapies. Instead, enrolment onto clinical trials should be standard-of-care in these patients.<br /> (© 2023. The Author(s).)
Details
- Language :
- English
- ISSN :
- 1534-6269
- Volume :
- 25
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- Current oncology reports
- Publication Type :
- Academic Journal
- Accession number :
- 36988735
- Full Text :
- https://doi.org/10.1007/s11912-023-01385-6